Matushansky Igor 4
4 · HOOKIPA Pharma Inc. · Filed Dec 18, 2020
Insider Transaction Report
Form 4
Matushansky Igor
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-12-16−640→ 39,735 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (640 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-17−31,656→ 8,079 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (31,656 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-17−11,367→ 14,208 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (11,367 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-17−5,965→ 7,669 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (5,965 underlying) - Exercise/Conversion
Common Stock
2020-12-16$0.10/sh+640$64→ 56,774 total - Sale
Common Stock
2020-12-16$11.70/sh−380$4,446→ 56,394 total - Sale
Common Stock
2020-12-17$11.70/sh−11,501$134,562→ 64,253 total - Exercise/Conversion
Common Stock
2020-12-17$0.10/sh+29,628$2,963→ 93,881 total - Sale
Common Stock
2020-12-17$11.76/sh−16,478$193,781→ 77,403 total - Exercise/Conversion
Common Stock
2020-12-17$0.10/sh+19,360$1,936→ 75,754 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
- [F2]25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 121,133 shares.
- [F3]25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 31,258 shares.
- [F4]25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 5,965 shares.